Alan W. Dunton - 30 Dec 2025 Form 4 Insider Report for CorMedix Inc. (CRMD)

Role
Director
Signature
/s/ Alan W. Dunton
Issuer symbol
CRMD
Transactions as of
30 Dec 2025
Net transactions value
-$179,400
Form type
4
Filing time
02 Jan 2026, 21:30:03 UTC
Previous filing
15 Dec 2025
Next filing
27 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DUNTON ALAN W Director C/O CORMEDIX INC.,, 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS /s/ Alan W. Dunton 02 Jan 2026 0001304773

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRMD Common Stock Options Exercise $80,600 +20,000 +50% $4.03 60,250 30 Dec 2025 Direct
transaction CRMD Common Stock Sale $260,000 -20,000 -33% $13.00 40,250 30 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRMD Stock Option (Right to Buy Common Stock) Options Exercise $0 -20,000 -100% $0.000000 0 30 Dec 2025 Common Stock 20,000 $4.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These options were granted on 2/22/2022. These options are fully vested.